Glioma Market Size in the 7MM was ~USD 1000 Million in 2023, and it is expected to grow by 2034, according to DelveInsight

The Glioma Market Size in the 7MM was valued at ~USD 1000 Million in 2023 and is projected to grow at a robust CAGR during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Glioma Market Landscape. By analyzing historical data, current Glioma Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Glioma Market is increasingly guided by biomarker-driven strategies. Glioma is a malignant bone tumor that originates from cartilage-producing cells. Glioma is a type of tumor that develops in the brain or spinal cord from glial cells, which are supportive cells that surround and protect nerve cells (neurons). These tumors can be either benign (slow-growing) or malignant (aggressive and fast-growing), depending on the type and grade.

DelveInsight’s report, “Glioma Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Glioma Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Glioma Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Glioma Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Glioma Market Forecast

Key Takeaways from Glioma Market Report

• The United States contributed to the largest incident population of glioma, acquiring ~40% of the 7MM in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2023.
• According to DelveInsight estimates, in the US, among all the grades, Grade IV accounted for the highest number of incident cases (~68%), followed by Grade II glioma (~13%), while Grade I had the least number of cases (~6%).
• The major types of glioma include diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytic tumors, pilocytic astrocytoma, and others. In 2023, glioblastoma contributed to the highest number of glioma cases i.e., around 67% of the total population.
• In the US, among all the age groups, 60–74 years accounted for the highest number of glioma cases, i.e., around 36%, in 2023, followed by the age-group 45–59 years (25%).
• The leading Glioma Companies such as Memorial Sloan Kettering Cancer Center, AnHeart Therapeutics Inc., Eli Lilly and Company, Chimerix, Plus Therapeutics, Chimerix, Istari Oncology, Inc., Armando Santoro, MD, Epitopoietic Research Corporation, Aveta Biomics, Inc., Chimerix, Day One Biopharmaceuticals, Incyte Corporation, Nerviano Medical Sciences, Daiichi Sankyo Co., Ltd., Everfront Biotech Co., Ltd., Ashish Shah, Oblato, Inc., Day One Biopharmaceuticals, BioMimetix JV, LLC, and others.
• Promising Glioma Therapies such as Pembrolizumab, Safusidenib, Abemaciclib, ONC201, Rhenium Liposome Treatment, ONC201, PVSRIPO, Temodal, ERC1671, APG-157, ONC201, Tovorafenib, Pemigatinib, NMS-03305293, DS-1001b, Cerebraca wafer, DB107-RRV, OKN-007, DAY101, BMX-001, and others.

Glioma Overview

Glioma is a type of tumor that originates from glial cells in the brain or spinal cord. Glial cells are supportive cells that surround and protect neurons, providing structural support, insulation, and nutrients. Gliomas are the most common type of primary brain tumors in adults and can vary significantly in their aggressiveness and growth rate.

Get a Free sample for the Glioma Market Report @ https://www.delveinsight.com/report-store/glioma-market

Key Factors in Glioma Therapeutics Market

• High Unmet Clinical Needs

Gliomas, especially high-grade tumors such as glioblastoma multiforme (GBM), are associated with poor prognosis, rapid progression, and limited responsiveness to standard treatments like surgery, radiation, and temozolomide. This persistent unmet clinical need is a primary driver for innovation and investment in the therapeutic landscape.

• Advancements in Molecular Understanding

Breakthroughs in genomic profiling and molecular characterization of gliomas (e.g., IDH mutation status, MGMT promoter methylation) have facilitated the identification of novel therapeutic targets. Precision medicine approaches are guiding development of targeted therapies and personalized treatment regimens.

• Emergence of Immunotherapies and Targeted Modalities

The market is witnessing increased activity in immunotherapies (e.g., checkpoint inhibitors, CAR-T cell therapies), oncolytic viral therapies, and other biologic agents aimed at modulating the tumor microenvironment. Targeted therapies based on actionable mutations (e.g., FGFR, EGFR, BRAF) are also progressing through clinical pipelines.

• Growth in Clinical Development Activity

Robust clinical trial activity—spanning early-phase exploratory studies to pivotal trials—reflects growing industry commitment. Multiple therapeutic candidates in different mechanisms of action are in development, broadening pipeline diversity and fostering competitive dynamics.

• Regulatory Incentives and Designations

Regulatory agencies, including the U.S. FDA and EMA, are providing incentives such as Breakthrough Therapy Designations, Orphan Drug Status, and accelerated pathways for therapies addressing serious conditions like gliomas. These incentives can shorten development timelines, improve patient access, and enhance commercial potential.

• Rising Healthcare Expenditure and Awareness

Increasing healthcare spending in developed and emerging markets, coupled with rising awareness among clinicians and patients about early diagnosis and treatment options, is expected to support market expansion. Improved diagnostic imaging and biomarker testing are also contributing to earlier detection.

• Competitive and Strategic Collaborations

Strategic partnerships, licensing agreements, and mergers & acquisitions among pharmaceutical companies, biotech firms, research institutions, and academic centers are boosting innovation. Such collaborations enable resource sharing, risk mitigation, and accelerated therapeutic development.

• Geographic Market Dynamics

North America currently dominates the glioma therapeutics market due to advanced research infrastructure, favorable regulatory environments, and strong industry presence. However, emerging markets in Asia-Pacific and Latin America are gaining traction owing to growing healthcare investments and increasing incidence rates.

Glioma Epidemiology Segmentation in the 7MM

The Glioma Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into-

• Total Incident Population of Glioma
• Grade-specific Incident Population of Glioma
• Type-specific Population of Highgrade Glioma (including Diffuse Midline Glioma, Glioblastoma, and others
• Type-specific Population of Lowgrade Glioma (including Diffuse astrocytoma, PilocyticAstrocytoma, and others)
• Age-specific Population of Glioma
• Glioma Cases Based on Molecular Alterations

Download the report to understand which factors are driving Glioma Epidemiology trends @ Glioma Epidemiology Forecast

Recent Development in the Glioma Treatment Landscape

• On February 05, 2026- Institute of Cancer Research, United Kingdom initiated a clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy. In the Phase 1b of this study parallel biomarker defined arms will be opened in the front-line unmethylated MGMT setting, enrolling 10 patients onto each arm. These patients will be treated with paxalisib in combination with temozolomide (TMZ). The starting dose of paxalisib will be 45mg once a day (OD) with the option of increasing to 60 mg (30 mg BD) in Cycle 2. TMZ will be administered once daily by mouth on days 1 to 5 in a 28-day cycle, with a starting dose of 150mg/m2 during cycles 1 and 2, and subsequent dose escalation to 200mg/m2 at the start of cycle 3 if cycles 1 and 2 have been well tolerated with no significant toxicity.
• On February 04, 2026- St. Jude Children's Research Hospital conducted a Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
• On February 03, 2026- Nuvation Bio Inc. announced a study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma.

Glioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Glioma drugs recently launched in the Glioma market or expected to get launched during the study period. The analysis covers Glioma Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glioma Companies and Therapies

• Pembrolizumab: Memorial Sloan Kettering Cancer Center
• safusidenib: AnHeart Therapeutics Inc.
• Abemaciclib: Eli Lilly and Company
• ONC201: Chimerix
• Rhenium Liposome Treatment: Plus Therapeutics
• ONC201: Chimerix
• PVSRIPO: Istari Oncology, Inc.
• Temodal: Armando Santoro, MD
• ERC1671: Epitopoietic Research Corporation
• APG-157: Aveta Biomics, Inc.
• ONC201: Chimerix
• Tovorafenib: Day One Biopharmaceuticals
• Pemigatinib: Incyte Corporation
• NMS-03305293: Nerviano Medical Sciences
• DS-1001b: Daiichi Sankyo Co., Ltd.
• Cerebraca wafer: Everfront Biotech Co., Ltd.
• DB107-RRV: Ashish Shah
• OKN-007: Oblato, Inc.
• DAY101: Day One Biopharmaceuticals
• BMX-001: BioMimetix JV, LLC

To know more about Glioma Companies working in the treatment market, visit @ Glioma Clinical Trials and Therapeutic Assessment

Glioma Market Drivers

• Rising Incidence of Primary Brain Tumors

The increasing diagnosis of primary brain tumors, including gliomas such as glioblastoma and astrocytoma, is a major growth driver. Improved neuroimaging techniques and heightened awareness have led to earlier and more frequent detection, thereby expanding the eligible patient pool for treatment.

• Advancements in Molecular Diagnostics

The integration of molecular biomarkers such as IDH mutation status, 1p/19q co-deletion, and MGMT promoter methylation into clinical practice has transformed glioma classification and treatment selection. Precision medicine approaches are enhancing targeted therapy adoption, supporting market expansion.

• Robust Pipeline and Emerging Therapies

A strong pipeline of novel therapeutics—including immunotherapies, CAR-T cell therapies, oncolytic viruses, tumor-treating fields, and targeted small molecules—is fueling optimism in the glioma market. Increasing clinical trial activity and regulatory incentives for orphan indications further accelerate development timelines.

• Growing Investment in Neuro-Oncology Research

Pharmaceutical and biotechnology companies are significantly increasing investments in neuro-oncology research. Strategic collaborations, licensing agreements, and funding initiatives from public and private organizations are contributing to innovation and commercialization efforts.

• Increasing Adoption of Combination Therapies

Combination regimens integrating surgery, radiotherapy, chemotherapy, and emerging targeted agents are becoming standard practice. The shift toward multimodal treatment approaches is driving demand for both established and novel therapies.

• Expanding Use of Tumor Treating Fields

The growing clinical acceptance of tumor-treating fields as an adjunct therapy for glioblastoma is positively impacting market growth. Improved survival outcomes and supportive clinical data are encouraging broader adoption in treatment protocols.

• Favorable Regulatory Designations

Orphan drug designation, fast-track approvals, and breakthrough therapy status for innovative glioma treatments are expediting regulatory pathways. These incentives are encouraging companies to invest in high-risk, high-reward neuro-oncology programs.

• Rising Healthcare Expenditure in Key Markets

Increased healthcare spending across the US, EU5, and Japan is enhancing patient access to advanced therapeutics. Reimbursement support for high-cost oncology drugs is further strengthening the commercial landscape.

• Technological Advancements in Neurosurgery and Radiation

Improvements in minimally invasive neurosurgical techniques, intraoperative imaging, and precision radiotherapy are improving treatment outcomes. These advancements indirectly support pharmaceutical uptake by improving survival and extending treatment duration.

• Growing Focus on Personalized Medicine

The shift toward biomarker-driven therapies and patient stratification strategies is enhancing therapeutic efficacy and clinical trial success rates. Personalized medicine trends are expected to significantly influence long-term market growth.

Glioma Market Barriers

• Complex Tumor Biology

The Glioma Market is significantly hindered by the highly heterogeneous and aggressive nature of gliomas. Variations in molecular profiles, including differences in IDH mutation status and other genetic alterations, complicate treatment standardization and reduce the overall success rate of targeted therapies. Tumor adaptability and resistance mechanisms further limit long-term therapeutic efficacy.

• Blood–Brain Barrier (BBB) Challenges

One of the most critical barriers in glioma treatment development is the blood–brain barrier, which restricts drug penetration into brain tissues. Many promising systemic therapies fail to reach adequate therapeutic concentrations within the tumor microenvironment, increasing R&D complexity and failure rates in clinical trials.

• High Recurrence and Poor Prognosis

Gliomas, particularly high-grade variants such as glioblastoma, are associated with high recurrence rates despite aggressive treatment approaches. Limited second-line treatment options and short progression-free survival durations negatively impact market sustainability and patient outcomes.

• Limited Therapeutic Breakthroughs

The standard of care—comprising surgery, radiation therapy, and chemotherapy—has remained largely unchanged over the years. Numerous late-stage clinical trials have failed to demonstrate substantial improvements in overall survival, and immunotherapy has shown limited success in this indication, slowing innovation within the Glioma Market.

• Stringent Regulatory Pathways

Regulatory agencies require robust survival data and clinically meaningful endpoints, which often lead to prolonged and costly clinical development programs. The need to demonstrate clear overall survival benefits further increases the risk of trial failure.

• Small and Segmented Patient Pool

Although glioma represents a critical unmet need, it is relatively rare compared to other oncology indications. Molecular subtyping further segments the patient population, limiting the commercial potential and return on investment for pharmaceutical companies.

• Clinical Trial Recruitment Challenges

Recruiting eligible patients for glioma trials is difficult due to strict inclusion criteria, rapid disease progression, and competition among ongoing studies, thereby delaying product development timelines.

Scope of the Glioma Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Glioma Companies- Memorial Sloan Kettering Cancer Center, AnHeart Therapeutics Inc., Eli Lilly and Company, Chimerix, Plus Therapeutics, Chimerix, Istari Oncology, Inc., Armando Santoro, MD, Epitopoietic Research Corporation, Aveta Biomics, Inc., Chimerix, Day One Biopharmaceuticals, Incyte Corporation, Nerviano Medical Sciences, Daiichi Sankyo Co., Ltd., Everfront Biotech Co., Ltd., Ashish Shah, Oblato, Inc., Day One Biopharmaceuticals, BioMimetix JV, LLC, and others.
• Glioma Therapies- Pembrolizumab, Safusidenib, Abemaciclib, ONC201, Rhenium Liposome Treatment, ONC201, PVSRIPO, Temodal, ERC1671, APG-157, ONC201, Tovorafenib, Pemigatinib, NMS-03305293, DS-1001b, Cerebraca wafer, DB107-RRV, OKN-007, DAY101, BMX-001, and others.
• Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies
• Glioma Market Dynamics: Glioma market drivers and Glioma market barriers
• Glioma Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Glioma Unmet Needs, KOL’s views, Analyst’s views, Glioma Market Access and Reimbursement

Discover more about therapies set to grab the major Glioma Market Share @ Glioma Treatment Market

Table of Contents

1. Key Insights

2. Glioma Market Report Introduction

3. Glioma Executive Summary

4. Glioma Key Events

5. Glioma Epidemiology and Market Forecast Methodology

6. Glioma Market Overview at a Glance

7. Glioma Disease Background and Overview

8. Glioma Epidemiology and Patient Population

9. Glioma Patient Journey

10. Glioma Marketed Drugs

11. Glioma Emerging Drugs

12. Glioma: 7MM Analysis

13. Glioma Unmet Needs

14. Glioma SWOT Analysis

15. Glioma KOL Views

16. Glioma Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.